Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371292 | 0.79 | RAB9A (0.42) | MEN1MAPTKMT2A | |
| SCHEMBL29040538 | 0.78 | RAB9A (0.41) | MEN1MAPTKMT2A | |
| SCHEMBL7929544 | 0.77 | CYP1A2 (0.34) | MAPTCYP2C9KMT2A | |
| SCHEMBL18762840 | 0.76 | CHRNA7 (0.43) | ACHEBCHEPYCR1ALOX5FAAH | |
| SCHEMBL16291506 | 0.75 | SLC2A1 (0.53) | ACHEALOX5MEN1KMT2AAOC3 | |
| SCHEMBL27957983 | 0.74 | CYP11B1 (0.36) | ALOX5MEN1MAPTCYP2C9KMT2A | |
| SCHEMBL2554730 | 0.74 | CA2 (0.44) | MEN1MAPTCYP2C9KMT2A | |
| SCHEMBL3800806 | 0.73 | CA1 (0.38) | MEN1KMT2A | |
| SCHEMBL10087250 | 0.73 | PDE2A (0.51) | MAPT | |
| SCHEMBL28291853 | 0.73 | ALDH1A1 (0.53) | MEN1MAPTCYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102917590-A | Trycyclic compounds and pbk inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-02-06 | — | — | CN | disclosed |